Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

NCT07400952

Status	RECRUITING
Phase	Phase 2
Sponsor	Glaukos Corporation
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (2)

- Be e 18 and d 55 years of age
- Diagnosis of keratoconus in the study eye

Exclusion (2)

- Pregnant, lactating or planning a pregnancy
- Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial

Locations (1 total)

Glaukos Clinical Study Site, Westerville, Ohio, United States